Cardiovascular risk markers during treatment with estradiol and trimegestone or dydrogesterone

Development of a new test for the global fibrinolytic capacity in whole blood

Effects of non-oral postmenopausal hormone therapy on markers of cardiovascular risk: A systematic review

Inhibitors and activation markers of the haemostatic system during hormone therapy: A comparative study of oral estradiol (2 mg)/ dydrogesterone and estradiol (2 mg)/ trimegestone

Comparative effects of a contraceptive vaginal ring delivering a nonandrogenic progestin and continuous ethinyl estradiol and a combined oral contraceptive containing levonorgestrel on hemostasis variables

Discovery of thrombin activatable fibrinolysis inhibitor (TAFI)

A prospective study on the effects on hemostasis of two oral contraceptives containing drospirenone in combination with either 30 or 20 μg ethinyl estradiol and a reference containing desogestrel and 30 μg ethinyl estradiol

Fibrinolytic efficacy of amediplase, tenecteplase and scu-PA in different external plasma clot lysis models

The effects of 12 weeks of HMR 3339, a novel selective estrogen receptor modulator, on markers of coagulation and fibrinolysis: A randomized, placebo-controlled, double-blind, dose-ranging study in healthy postmenopausal women

Association between thrombin activatable fibrinolysis inhibitor genotype and levels in plasma: Comparison of different assays

Preeclampsia and its interaction with common variants in thrombophilia genes

Clot penetration and fibrin binding of amediplase, a chimeric plasminogen activator (K2tu-PA)

Stabilization versus inhibition of TAFIa by competitive inhibitors in vitro

Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor/vascular endothelial growth factor receptor pathway in cancer patients

Time course of peritoneal tissue plasminogen activator after experimental colonic surgery: Effect of hyaluronan-based antiadhesive agents and bacterial peritonitis

Adenovirus-mediated transfer of the 39 kD receptor-associated protein increases fibrinolytic capacity

Oral, but not transdermal, administration of estrogens lowers tissue- type plasminogen activator levels in humans without affecting endothelial synthesis

Acceleration of fibrinolysis by high-frequency ultrasound: The contribution of acoustic streaming and temperature rise

Reduced activity of TAFI (thrombin-activatable fibrinolysis inhibitor) in acute promyelocytic leukaemia

Urokinase-mediated fibrinolysis in the synovial fluid of rheumatoid arthritis patients may be affected by the inactivation of single chain urokinase type plasminogen activator by thrombin